CORONA Remedies FY26: Strong growth, higher profitability, and a wider strategic canvas

CORONA Remedies ended FY26 with a faster growth profile than the broader Indian Pharmaceutical Market (IPM), supported by brand execution, a chronic-heavy portfolio, and continued inorganic expansion. Consolidated revenue from operations rose to INR 1,403.2 crore in FY26, up 17.3% year-on-year. EBITDA grew 22.3% to INR 293.4 crore, with margin improving to 20.9%. Adjusted profit after tax came in at INR 199.4 crore, up 33.4%, after excluding a one-time statutory impact related to the new labor code.

In Q4FY26, revenue reached INR 353.1 crore, up 20.2% year-on-year. EBITDA increased to INR 62.0 crore, up 14.4%, but margin softened to 17.6%. Management attributed the margin dip to deliberate growth investments during the quarter, including costs linked to two new divisions, higher medical representative spend, and higher R and D expenditure.

FY26 performance: growth with margin expansion

The company’s FY26 gross margin improved to 81.4% versus 80.2% in FY25, reflecting a stable product and pricing profile. Employee cost and other expenses rose as the company expanded field force and supported brand activity, but overall operating leverage remained favorable for the full year, reflected in the 80 basis point improvement in EBITDA margin.

Cash generation remained a key support. Net cash from operating activities was INR 229.5 crore in FY26, and OCF to EBITDA conversion was reported at 78.2%. Management also highlighted strong return ratios, with FY26 ROCE at 40.8% and ROE at 29.2%, stated as excluding the one-time labor code impact.

Financial summary

Note: FY26 adjusted PAT excludes a one-time statutory impact of INR 19.1 crore (post-tax INR 14.3 crore) related to the new labor code.

Portfolio mix: chronic skew and “engine brands” discipline

CORONA’s strategy continues to lean into chronic and sub-chronic therapies, which management linked to higher prescription stickiness and longer patient lifecycles. Chronic and sub-chronic therapies contributed 71.9% of FY26 revenue and 72.3% in Q4FY26, as per the presentation. This also aligns with the company’s stated shift in portfolio mix over time toward chronic therapies.

The company positions its brand execution through an “engine brands” approach. The presentation states that 32 engine brands contributed about 76% of domestic sales over MAT Mar-23 to MAT Mar-26, with about 19% CAGR in that period. The top five brands listed were B-29, Myoril, Tricium, Cortel, and Obimet. The company also highlighted that its top 10 brands account for 50.4% of revenue, which supports diversification relative to a single brand-led profile, while still indicating that execution on a concentrated set of large brands remains important.

Inorganic moves and new platforms: Wokadine, Bayer portfolio, and biologics

A key FY26 development was the acquisition of Wokadine from Dr. Reddy’s Laboratories. Management described Wokadine as ranked second in the Indian povidone iodine market. On the call, management referred to it as an approximately INR 20 crore brand and guided to about 25% revenue growth for at least 3 to 4 years. Management also stated the portfolio has multiple SKUs, with strategy adjustments to emphasize the non-NLEM parts of the range.

Alongside Wokadine, the company referenced the Bayer Zydus portfolio of seven brands, with relaunch initiated in Q4FY26. Management highlighted Menodac and Fostine R as the two arrowhead brands in the infertility-focused portfolio and stated an initial aim to scale the portfolio toward INR 50 crore to INR 100 crore.

Another expansion vector is biosimilars and biologics. Management stated the company launched products in this space in FY26, naming Fostine R, Tricium DnaB, Wyntide and Tyvenza. The call commentary suggested the company is open to both organic development and in-licensing, depending on the complexity and category.

Manufacturing and international readiness: certifications and capacity

CORONA’s Gujarat facility holds multiple quality certifications, including EU-GMP, EAEU-GMP and WHO-GMP, while the Himachal Pradesh facility is WHO-GMP certified. In January 2026, the Bhayla facility received EAEU-GMP certification, which enables access to Eurasian markets such as Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan.

Management clarified that scaling in these regulated geographies can take time. Product registrations were stated to typically require 1.5 to 2 years, and management indicated the European and Eurasian opportunity could take 2 to 3 years to meaningfully ramp as dossiers progress.

Capacity expansion also continued. The presentation states the Bhayla facility expanded tablet and capsule capacity with an additional 400 million units. The Gujarat facility’s commercial production addition was noted as having commenced on 22 December 2025.

A notable forward milestone is the dedicated hormone manufacturing plant, which management said is expected to become operational in Q1 or Q2 of FY27. This links with the company’s positioning in international markets, where management emphasized a hormone-focused proposition.

Outlook and what to watch

Management reiterated a medium-term framework of 15% year-on-year revenue growth and 20% year-on-year PAT growth. For FY27 specifically, management guided to sustaining 15% plus revenue growth organically and 20% plus PAT growth, and also referred to 25% revenue growth in acquired brands.

On margins, management stated an expectation to maintain gross margins around the 80% range. Still, the quarter highlighted that margins can be volatile when the company chooses to step up investments in divisions, field force, and R and D. Management also acknowledged potential input cost pressure linked to oil and broader API inflation dynamics, while stating it was too early to quantify the impact.

The company’s balance sheet commentary focused on being net cash, with borrowings largely linked to an overdraft against fixed deposits and short-term usage around the Wokadine acquisition.

Takeaways

CORONA’s FY26 performance combined strong top-line growth with improving profitability, despite a Q4 margin dip attributed to growth spending. The company is doubling down on chronic and sub-chronic therapies, scaling engine brands, and using acquisitions to broaden the platform. The next phase will likely be judged on execution of acquired brands, early traction in biosimilars and biologics, and the company’s ability to convert quality certifications into a steady international revenue stream over the stated multi-year timeline.